Fortis Healthcare Ltd (FORTIS) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Fortis Healthcare enters Q1 FY27 results with a focus on scaling its hospital network and navigating a complex regulatory environment for oncology services. Investors will be watching for progress on the 15% revenue growth target and early signs of margin expansion following recent government drug price adjustments.

Fortis Healthcare Ltd Q1 Results Date and Time

The board meeting is scheduled for August 6, 2026, to approve the un-audited standalone and consolidated financial results for Q1 FY27.

What to expect from Fortis Healthcare Ltd's Q1 FY27 results

Fortis is targeting a 15% plus revenue growth for the hospital business in FY27, supported by seasonal disease trends that saw 3,747 dengue cases in May 2026 and a progressive increase in vector-borne illnesses. The June 12, 2026, NPPA ruling to increase ceiling prices for chemotherapy drugs by 50% provides a direct margin tailwind, potentially reversing the occupancy drag caused by the previous unviable oncology drug pricing. While Q1 is seasonally softer than Q4, with Q1 FY26 consolidated revenue at Rs. 2,167 Cr, the company is managing a structural increase in finance costs following a year-end net debt of Rs. 2,334 Cr. Diagnostics margins are expected to stabilize toward the 23-24% range, supported by the expansion of 125+ customer touchpoints added in the previous quarter. Management's annual capex guidance of Rs. 900 Cr remains a key monitorable as the firm continues brownfield expansions at FMRI and other facilities.

Key Things To Watch

Performance vs Guidance Tracking: Monitoring progress against FY27 strategic targets.

• Hospital revenue growth target of 15%+ in FY27 — Q1 will provide the first trend data point.
• Hospital EBITDA margin improvement goal of 150 bps — Q1 margin vs Q1 FY26 (22.1%) is critical.
• Diagnostics EBITDA margin target of 23-24% — Q1 margin vs Q4 FY26 (22.0%).
• Diagnostics double-digit revenue growth — Q1 growth vs Q1 FY26 (6.3%).
• Occupancy target of above 70% — Q4 FY26 was 68%.

Strategic execution and capacity updates: Status of ongoing bed additions and management changes.

• FMRI expansion of 225 beds — first 100 beds expected to be phased by April FY27.
• Odisha O&M agreement with Dion Group — update on timeline for the 300-bed facility.
• Agilus Diagnostics — first quarterly call under new MD & CEO Mr. Vijender Singh.

Risks and headwinds to monitor: Management-flagged operational challenges.

• CGHS/ECHS oncology drug price impact — status of patient volume recovery following the June 12 NPPA price hike.
• International patient growth — monitoring if the Q4 FY26 slowdown to 11% persists.
• BG Road occupancy — targeting improvement above 60% after recent underperformance at 55%.